SCHEMBL2348488

SCHEMBL2348488

Cc1ccc(-n2c(Cl)c(C=O)c3ccccc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
HTT P42858 6/20 0.48
NPSR1 Q6W5P4 6/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 2/20 0.43
UBE2N P61088 1/20 0.43
LMNA P02545 4/20 0.41
ALDH1A1 P00352 3/20 0.41
ATM Q13315 1/20 0.41
NOD2 Q9HC29 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
KMT2A Q03164 1/20 0.41
RORC P51449 1/20 0.40
HPGD P15428 2/20 0.39
NPC1 O15118 1/20 0.39
HSP90AA1 P07900 1/20 0.39
XBP1 P17861 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2345150 0.88 NPSR1 (0.49) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL29954953 0.87 KDM4E (0.52) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL2343158 0.87 KDM4E (0.52) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL2341924 0.85 ALDH1A1 (0.48) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL2346039 0.85 LMNA (0.50) MAPTHTTNPSR1SMN1; SMN2L3MBTL1
SCHEMBL2347546 0.85 LMNA (0.47) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL2345076 0.85 HTT (0.38) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL2340463 0.84 PPARG (0.41) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL2345502 0.84 HPGD (0.54) MAPTHTTNPSR1SMN1; SMN2POLB
SCHEMBL2347831 0.84 KDM4E (0.39) MAPTHTTNPSR1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008491-B2 poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders AVENTIS PHARMACEUTICALS, INC. (US) 2011-08-30 US disclosed
US-20080255350-A1 SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2008-10-16 US disclosed
US-7405300-B2 Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) AVENTIS PHARMAVEUTICALS INC. (US) 2008-07-29 US disclosed
EP-1663202-A1 SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) Aventis Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005023246-A1 SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2005-03-17 WO disclosed
US-20050054631-A1 Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054631-A1 Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) PARP1, PARP11, PARP3 MAPT 2114/4885HTT 417/4885NPSR1 496/4885
US-20080255350-A1 SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP11, PARP15 MAPT 3033/4885HTT 626/4885NPSR1 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.